Margrit Kemper
Overview
Explore the profile of Margrit Kemper including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
247
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Meyer N, Kabisch S, Dambeck U, Honsek C, Kemper M, Gerbracht C, et al.
Int J Mol Sci
. 2024 Jun;
25(12).
PMID: 38928106
Lifestyle interventions can prevent type 2 diabetes (T2DM). However, some individuals do not experience anticipated improvements despite weight loss. Biomarkers to identify such individuals at early stages are lacking. Insulin-like...
2.
Zhang J, Sonnenburg D, Trico D, Kabisch S, Mari A, Theis S, et al.
Mol Nutr Food Res
. 2024 Feb;
68(4):e2300086.
PMID: 38332571
Scope: Secretion of the gut hormones glucagon-like peptide (GLP-1) and peptide YY (PYY) are induced by nutrients reaching the lower small intestine which regulate insulin and glucagon release, inhibit appetite,...
3.
Zhang J, Schafer S, Kabisch S, Csanalosi M, Schuppelius B, Kemper M, et al.
Clin Nutr
. 2023 Mar;
42(4):467-476.
PMID: 36857956
Aims: Amino acids powerfully release glucagon but their contribution to postprandial hyperglucagonemia in type 2 diabetes remains unclear. Exogenously applied GIP stimulates, while GLP-1 inhibits, glucagon secretion in humans. However,...
4.
Kabisch S, Meyer N, Honsek C, Kemper M, Gerbracht C, Arafat A, et al.
Nutrients
. 2022 Nov;
14(22).
PMID: 36432409
Background: T2DM heterogeneity affects responsiveness to lifestyle treatment. Beta-cell failure and nonalcoholic fatty liver disease (NAFLD) independently predict T2DM, but NAFLD inconsistently predicts metabolic response to lifestyle intervention. Aim: We...
5.
Meyer N, Kabisch S, Dambeck U, Honsek C, Kemper M, Gerbracht C, et al.
Eur J Endocrinol
. 2022 Aug;
187(4):555-565.
PMID: 36005859
Objectives: Some individuals develop type 2 diabetes mellitus (T2DM) despite significant metabolic improvements through lifestyle intervention. We tested the hypotheses that insulin growth factor 1 (IGF1) and its binding proteins...
6.
Kabisch S, Honsek C, Kemper M, Gerbracht C, Arafat A, Birkenfeld A, et al.
Acta Diabetol
. 2021 Jul;
58(12):1649-1658.
PMID: 34254189
Aims: As the first long-term RCT on insoluble cereal fibre, the optimal fibre trial demonstrated glycometabolic benefits, confirming cohort studies. The combined study intervention of lifestyle recommendations and supplementation with...
7.
Kabisch S, Honsek C, Kemper M, Gerbracht C, Meyer N, Arafat A, et al.
Mol Nutr Food Res
. 2021 Apr;
65(12):e2000991.
PMID: 33909947
Scope: The Optimal Fibre Trial (OptiFiT) investigates metabolic effects of insoluble cereal fibre in subjects with impaired glucose tolerance (IGT), showing moderate glycemic and anti-inflammatory benefits, especially in subjects with...
8.
Kruse M, Kemper M, Gancheva S, Osterhoff M, Dannenberger D, Markgraf D, et al.
Mol Nutr Food Res
. 2020 Sep;
64(21):e2000419.
PMID: 32920973
Scope: Effective treatment for obesity associated non-alcoholic fatty liver disease (NAFLD) is limited. Dietary supplementation of n-3 polyunsaturated fatty acids, specifically alpha linolenic acid (ALA), can resolve intrahepatic lipid content...
9.
Keyhani-Nejad F, Barbosa Yanez R, Kemper M, Schueler R, Pivovarova-Ramich O, Rudovich N, et al.
Peptides
. 2019 Dec;
125:170231.
PMID: 31870938
GIP was proposed to play a key role in the development of non- alcoholic fatty liver disease (NAFLD) in response to sugar intake. Isomaltulose, is a 1,6-linked glucose-fructose dimer which...
10.
Kabisch S, Meyer N, Honsek C, Gerbracht C, Dambeck U, Kemper M, et al.
Nutrients
. 2019 Nov;
11(11).
PMID: 31717901
Background: OptiFiT demonstrated the beneficial effect of insoluble oat fibres on dysglycemia in prediabetes. Recent analyses of OptiFiT and other randomised controlled trials (RCTs) indicated that this effect might be...